Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
500 participants
OBSERVATIONAL
2025-02-28
2031-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Participants will be assessed at two main timepoints, at visit 1 (Week 0) and at visit 2 (4 +/-2 weeks). For participants with psychosis symptoms visit 1 will take place at the start or change of antipsychotic medication. The studies goal is to identify biomarkers that can aid in diagnosis, prognosis, treatment selection, and tracking treatment response.
The investigators aim to recruit participants from the following groups:
1. Individuals with psychosis symptoms presenting to acute or outpatient services who are due to be started on or change to a new regular antipsychotic medication.
2. Age- and sex-matched control participants without neuropsychiatric disease.
Findings could potentially impact the treatment of psychotic illnesses by offering mechanistic insights into targeted immune-based interventions for these disorders through high-resolution immunophenotyping techniques alongside targeted immunological assays. Ultimately, the research aims to contribute valuable resources for future studies exploring the connection between immune processes and neuropsychiatric conditions.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Peripheral Immune System in Individuals With Schizophrenia
NCT05109065
Investigation of Neurophysiological Markers, Possibly Specific of Two Subforms of Psychotic Disorders
NCT03649581
Study of Immunotherapy in Autoantibody Positive Psychosis
NCT02449746
Karolinska Schizophrenia Project
NCT06872463
Behavioral Intervention to Reduce Novel Antipsychotic Medication Health Risks
NCT00709345
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Participants with psychosis symptoms
No interventions assigned to this group
Control Participants
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age 18-65
* Currently experiencing psychosis symptoms warranting treatment by secondary care mental health services, as confirmed by a psychiatrist involved in their treatment.
* Psychosis symptoms likely to be attributable to a disorder represented by ICD codes F20-F39, in the opinion of the treating clinical team.
* Due to start or change to a new regular antipsychotic medication. (Participants who are initiating antipsychotic treatment for the first time, transitioning to a different antipsychotic medication, or resuming a formerly prescribed antipsychotic medication that was discontinued for a minimum of two weeks may be recruited.)
Control Participants
* Age 18-65
* No active autoimmune disorder.
* No history of psychosis symptoms.
Exclusion Criteria
* Unacceptable risk of harm to participant or study staff due to risk of behavioural disturbance.
* Currently taking or having taken in the last four weeks any medication known to grossly affect the production or function of immune cells (e.g. corticosteroids, methotrexate, cyclophosphamide, mycophenolate mofetil, rituximab or other monoclonal antibody therapies).
* Inability to have blood tests.
Control participants:
* Unacceptable risk of harm to participant or study staff due to risk of behavioural disturbance.
* Currently taking or having taken in the last four weeks any medication known to grossly affect the production or function of immune cells (e.g. corticosteroids, methotrexate, cyclophosphamide, mycophenolate mofetil, rituximab or other monoclonal antibody therapies).
* Inability to have blood tests.
Optional lumbar puncture only:
* Significant lower spinal deformity (such as spina bifida), injury (such as stenosis) or previous lower spinal surgery.
* Antiplatelet or anticoagulant therapy within the 14 days prior to Lumbar Puncture procedure.
* Known or suspected clotting disorder.
* Clinically significant abnormality in full blood count.
* Known or suspected raised intracranial pressure, assessed by study clinician.
* Known or suspected allergy to local anaesthetic agent or an ingredient of the anaesthetic solution.
* History of chronic or recurrent headaches, in the opinion of the investigator.
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
South London and Maudsley NHS Foundation Trust
OTHER
University of Oxford
OTHER
McPin Foundation
OTHER
Francis Crick Institute
OTHER
King's College London
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
South London and Maudsley NHS Foundation Trust
London, United Kingdom, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
331728
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.